{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/62d20dbcffef490011c8df4b/67e3c78823c4b9934b84cf0a?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"151. Back to Basics - Androgen Receptor Pathway Inhibitors in Metastatic Prostate Cancer","description":"<p>The rise and rise of Androgen Receptor Pathway (or Signalling) Inhibitors has changed the world of metastatic prostate cancer forever. What was once a cancer with a finite number of treatment options has flourished into a chasm of therapies, many more effective and less toxic than their therapeutic grandparents.</p><p><br></p><p><strong>Studies discussed in the episode:</strong></p><p><a href=\"https://pubmed.ncbi.nlm.nih.gov/31329516/\" rel=\"noopener noreferrer\" target=\"_blank\">ARCHES</a></p><p><a href=\"https://www.nejm.org/doi/full/10.1056/NEJMoa1903835\" rel=\"noopener noreferrer\" target=\"_blank\">ENZAMET</a></p><p><br></p><p>For more episodes, resources and blog posts, visit <a href=\"https://open.acast.com/networks/62d20dbcffef490011c8df4d/shows/62d20dbcffef490011c8df4b/episodes/www.inquisitiveonc.com\" rel=\"noopener noreferrer\" target=\"_blank\">www.inquisitiveonc.com</a></p><p>Please find us on Twitter <a href=\"https://open.acast.com/networks/62d20dbcffef490011c8df4d/shows/62d20dbcffef490011c8df4b/episodes/@InquisitiveOnc!\" rel=\"noopener noreferrer\" target=\"_blank\">@InquisitiveOnc!</a></p><p>If you want us to look at a specific trial or subject, email us at <a href=\"mailto:inquisitiveonc@gmail.com\" rel=\"noopener noreferrer\" target=\"_blank\">inquisitiveonc@gmail.com</a></p><p><br></p><p>Art courtesy of Taryn Silver</p><p>Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/</p><p><br></p><p>Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.</p><p><br></p><p>Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content.</p><p><br></p><p><br></p>","author_name":"Michael Fernando and Josh Hurwitz"}